Evidence map›Paper›PMID 30451076›Full record

ReviewNanomedicine (London, England)2019

Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities.

Fatemeh Farjadian, Amir Ghasemi, Omid Gohari, Amir Roointan, Mahdi Karimi, Michael R Hamblin

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nanomedicine (London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 196 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
196citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

196 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article

136 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Fatemeh FarjadianPharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz 71468-64685, Iran.
Amir GhasemiDepartment of Materials Science & Engineering, Sharif University of Technology, Tehran 11365-9466, Iran.
Omid GohariDepartment of Materials Science & Engineering, Sharif University of Technology, Tehran 11365-9466, Iran.
Amir RoointanDepartment of Medical Biotechnology, School of Advanced Medical Sciences & Technologies, Shiraz University of Medical Science, Shiraz 71348-14336, Iran.
Mahdi KarimiCellular & Molecular Research Center, Iran University of Medical Sciences, Tehran 14496-14535, Iran.
Michael R HamblinWellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.

Funding

Photodynamic Therapy of Localized InfectionsR01AI050875 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI HAMBLIN, MICHAEL R · 2003 to 2017
$4.8M
Synergistic Photodynamic Therapy for Catherer-Associated Urinary Tract InfectionsR21AI121700 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI HAMBLIN, MICHAEL R · 2016 to 2017
$462k
NIAID NIH HHS R01 AI050875NIAID NIH HHS R21 AI121700
6 · The paper itself

Abstract

There has been a revolution in nanotechnology and nanomedicine. Since 1980, there has been a remarkable increase in approved nano-based pharmaceutical products. These novel nano-based systems can either be therapeutic agents themselves, or else act as vehicles to carry different active pharmaceutical agents into specific parts of the body. Currently marketed nanostructures include nanocrystals, liposomes and lipid nanoparticles, PEGylated polymeric nanodrugs, other polymers, protein-based nanoparticles and metal-based nanoparticles. A range of issues must be addressed in the development of these nanostructures. Ethics, market size, possibility of market failure, costs and commercial development, are some topics which are on the table to be discussed. After passing all the ethical and biological assessments, and satisfying the investors as to future profitability, only a handful of these nanoformulations, successfully obtained marketing approval. We survey the range of nanomedicines that have received regulatory approval and are marketed. We discuss ethics, costs, commercial development and possible market failure. We estimate the global nanomedicine market size and future growth. Our goal is to summarize the different approved nanoformulations on the market, and briefly cover the challenges and future outlook.

Indexed as

Chemistry, PharmaceuticalDrug Delivery SystemsExcipientsHumansLegislation, DrugLiposomesMetalsNanomedicineNanoparticlesPolymersExcipientsLiposomesMetalsPolymersdrug deliverymarket sizenanocrystalnanodrugnanoliposomenanomedicinenanopharmaceuticalsnanopolymernanotechnologyregulatory approval

Identifiers

PMID30451076
PMCPMC6391637

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.